Aspen Pharmacare Competitors

OMRON (OTCMKTS:OMRNY) and Aspen Pharmacare (OTCMKTS:APNHY) are both computer and technology companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, earnings, risk and dividends.

Analyst Recommendations

This is a summary of current ratings and target prices for OMRON and Aspen Pharmacare, as provided by MarketBeat.

Insider and Institutional Ownership

0.9% of OMRON shares are owned by institutional investors. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares OMRON and Aspen Pharmacare's revenue, earnings per share and valuation.

OMRON has higher revenue and earnings than Aspen Pharmacare.

Volatility and Risk

OMRON has a beta of 1.19, suggesting that its share price is 19% more volatile than the S&P 500. Comparatively, Aspen Pharmacare has a beta of 1.53, suggesting that its share price is 53% more volatile than the S&P 500.

Profitability

This table compares OMRON and Aspen Pharmacare's net margins, return on equity and return on assets.

Summary

OMRON beats Aspen Pharmacare on 4 of the 5 factors compared between the two stocks.

Deutsche Wohnen (OTCMKTS:DWHHF) and Aspen Pharmacare (OTCMKTS:APNHY) are both finance companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, profitability, analyst recommendations and dividends.

Risk & Volatility

Deutsche Wohnen has a beta of 0.23, meaning that its stock price is 77% less volatile than the S&P 500. Comparatively, Aspen Pharmacare has a beta of 1.53, meaning that its stock price is 53% more volatile than the S&P 500.

Valuation and Earnings

This table compares Deutsche Wohnen and Aspen Pharmacare's top-line revenue, earnings per share and valuation.

Deutsche Wohnen has higher earnings, but lower revenue than Aspen Pharmacare. Deutsche Wohnen is trading at a lower price-to-earnings ratio than Aspen Pharmacare, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Deutsche Wohnen and Aspen Pharmacare, as reported by MarketBeat.

Profitability

This table compares Deutsche Wohnen and Aspen Pharmacare's net margins, return on equity and return on assets.

Summary

Deutsche Wohnen beats Aspen Pharmacare on 8 of the 10 factors compared between the two stocks.

OMV Aktiengesellschaft (OTCMKTS:OMVJF) and Aspen Pharmacare (OTCMKTS:APNHY) are both oils/energy companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, profitability, valuation, risk and earnings.

Risk and Volatility

OMV Aktiengesellschaft has a beta of 1.03, suggesting that its stock price is 3% more volatile than the S&P 500. Comparatively, Aspen Pharmacare has a beta of 1.53, suggesting that its stock price is 53% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations and price targets for OMV Aktiengesellschaft and Aspen Pharmacare, as provided by MarketBeat.com.

Earnings & Valuation

This table compares OMV Aktiengesellschaft and Aspen Pharmacare's revenue, earnings per share and valuation.

OMV Aktiengesellschaft has higher revenue and earnings than Aspen Pharmacare. OMV Aktiengesellschaft is trading at a lower price-to-earnings ratio than Aspen Pharmacare, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares OMV Aktiengesellschaft and Aspen Pharmacare's net margins, return on equity and return on assets.

Summary

OMV Aktiengesellschaft beats Aspen Pharmacare on 5 of the 9 factors compared between the two stocks.

Aspen Pharmacare (OTCMKTS:APNHY) and Surgutneftegas Public Joint Stock (OTCMKTS:SGTZY) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, dividends, earnings, valuation, profitability, risk and institutional ownership.

Profitability

This table compares Aspen Pharmacare and Surgutneftegas Public Joint Stock's net margins, return on equity and return on assets.

Risk and Volatility

Aspen Pharmacare has a beta of 1.53, suggesting that its share price is 53% more volatile than the S&P 500. Comparatively, Surgutneftegas Public Joint Stock has a beta of 1.2, suggesting that its share price is 20% more volatile than the S&P 500.

Insider & Institutional Ownership

0.0% of Surgutneftegas Public Joint Stock shares are held by institutional investors. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Aspen Pharmacare and Surgutneftegas Public Joint Stock's top-line revenue, earnings per share (EPS) and valuation.

Surgutneftegas Public Joint Stock has higher revenue and earnings than Aspen Pharmacare.

Analyst Ratings

This is a breakdown of current ratings for Aspen Pharmacare and Surgutneftegas Public Joint Stock, as provided by MarketBeat.

Summary

Surgutneftegas Public Joint Stock beats Aspen Pharmacare on 3 of the 5 factors compared between the two stocks.

Aspen Pharmacare (OTCMKTS:APNHY) and NN Group (OTCMKTS:NNGRY) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, analyst recommendations, earnings, risk, dividends, profitability and institutional ownership.

Analyst Recommendations

This is a summary of current recommendations and price targets for Aspen Pharmacare and NN Group, as provided by MarketBeat.com.

Insider and Institutional Ownership

0.4% of NN Group shares are owned by institutional investors. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Risk and Volatility

Aspen Pharmacare has a beta of 1.53, suggesting that its stock price is 53% more volatile than the S&P 500. Comparatively, NN Group has a beta of 1.07, suggesting that its stock price is 7% more volatile than the S&P 500.

Profitability

This table compares Aspen Pharmacare and NN Group's net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Aspen Pharmacare and NN Group's top-line revenue, earnings per share (EPS) and valuation.

NN Group has higher revenue and earnings than Aspen Pharmacare.

Summary

NN Group beats Aspen Pharmacare on 4 of the 7 factors compared between the two stocks.

Eurofins Scientific (OTCMKTS:ERFSF) and Aspen Pharmacare (OTCMKTS:APNHY) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, dividends, valuation and analyst recommendations.

Profitability

This table compares Eurofins Scientific and Aspen Pharmacare's net margins, return on equity and return on assets.

Volatility & Risk

Eurofins Scientific has a beta of 0.82, meaning that its share price is 18% less volatile than the S&P 500. Comparatively, Aspen Pharmacare has a beta of 1.53, meaning that its share price is 53% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings for Eurofins Scientific and Aspen Pharmacare, as reported by MarketBeat.

Valuation and Earnings

This table compares Eurofins Scientific and Aspen Pharmacare's revenue, earnings per share (EPS) and valuation.

Aspen Pharmacare has lower revenue, but higher earnings than Eurofins Scientific. Aspen Pharmacare is trading at a lower price-to-earnings ratio than Eurofins Scientific, indicating that it is currently the more affordable of the two stocks.

Summary

Eurofins Scientific beats Aspen Pharmacare on 5 of the 7 factors compared between the two stocks.